Arrowhead Research ARWR
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Arrowhead Research (ARWR)
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Key Insights
Critical company metrics and information
Latest Closing Price
$16.97Market Cap
$2.11 BillionPrice-Earnings Ratio
-3.39Total Outstanding Shares
124.20 Million SharesTotal Employees
525Dividend
No dividendIPO Date
January 6, 1997SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
177 e colorado blvd, Pasadena, CA, 91105Homepage
https://www.arrowheadpharma.com
Historical Stock Splits
If you bought 10 shares of ARWR before November 17, 2011, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| November 17, 2011 | 1-for-10 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $870.52 Million |
| Net Cash Flow | $-8.21 Million |
| Net Cash Flow From Operating Activities, Continuing | $-462.85 Million |
| Net Cash Flow, Continuing | $-12.40 Million |
| Net Cash Flow From Investing Activities | $-420.07 Million |
| Net Cash Flow From Financing Activities | $870.52 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Deferred | $0 |
| Basic Earnings Per Share | $-5 |
| Nonoperating Income/Loss | $-11.38 Million |
| Revenues | $3.55 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $-10.20 Million |
| Income/Loss From Continuing Operations Before Tax | $-612.46 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-601.72 Million |
| Comprehensive Income/Loss Attributable To Parent | $-601.72 Million |
| Other Comprehensive Income/Loss | $7.97 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $5.62 Million |
| Current Liabilities | $103.17 Million |
| Accounts Payable | $11.39 Million |
| Other Non-current Assets | $58.30 Million |
| Current Assets | $695.47 Million |
| Liabilities And Equity | $1.14 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ARWR from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.